KEYMED BIO has been included in the National Basic Medical Insurance Drug List
On December 7th, KEYMED BIO announced that its independently developed national Class 1 new drug Kangyueda® (Siponimod Injection) has been included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2025)," which will be officially implemented starting January 1, 2026
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments